

1 December 2016

### **Equity Research Report Released on Resonance Health Ltd**

Resonance Health (ASX: RHT) today announced the publication of an equity research report on the Company and the expanding future potential of the Company's quantitative medical imaging techniques for the diagnosis and clinical management of human disease.

The research was performed by NDF Research, an independent equity research firm who focus on life science companies publically listed on the Australian Stock Exchange (ASX). The goal of NDF Research is to introduce global investors to potential companies by way of sharing quality research.

The full report is available on the Resonance Health website:

[www.resonancehealth.com/investors/analyst-coverage](http://www.resonancehealth.com/investors/analyst-coverage)

Resonance Health develops and delivers medical imaging solutions and services to accurately and non-invasively quantify clinical parameters. This information assists clinicians in their diagnosis and management of human disease and supports pharmaceutical companies in the development of treatments. The Company's flagship product, FerriScan<sup>®</sup>, is globally recognised as the gold standard for measurement of liver iron concentration. FerriScan is also provided as a dual service together with an assessment of cardiac iron load. The Company's more recent product, HepaFat-Scan<sup>®</sup>, provides a measurement of volumetric liver fat fraction (VLFF) and is generating interest for improving outcomes for patients, including those with fatty liver disease.

Resonance Health is in an exciting phase of its history as it expands its portfolio of products and has also developed technologies for application in additional organs including the bone marrow, pancreas, and spleen. The Company continues work on pipeline products including tools for non-invasive measurement of liver fibrosis and inflammation. This investment in the expansion of the product suite and markets paves the way for ongoing future growth with vast market potential.

#### **For further information please contact:**

Sander Bangma

General Manager, Resonance Health

E: [SanderB@resonancehealth.com](mailto:SanderB@resonancehealth.com) P: +61 (0)8 9286 5300

---

#### **Resonance Health Ltd.**

278 Stirling Hwy, Claremont, WA 6010, AUSTRALIA  
[www.resonancehealth.com](http://www.resonancehealth.com)

T + 61 8 9286 5300

Postal: PO Box 1135, Nedlands, WA, 6909, AUSTRALIA  
[info@resonancehealth.com](mailto:info@resonancehealth.com)